Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G)

Efficacy and Safety of FOLFOXIRI plus Bevacizumab and Doublet plus Biologics in Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer: A Multi-institutional retrospective study (WJOG13219G) - A Multi-institutional retrospective study for Patients With Previously Untreated BRAF V600E-mutant Metastatic Colorectal Cancer (WJOG13219G)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041098

Enrollment

250

Registered

2020-07-15

Start date

2020-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BRAF V600E-mutant Metastatic Colorectal Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically confirmed colorectal cancer (CRC) 2) diagnosed unresectable or recurrent CRC and initiated first-line chemotherapy including two or all of fluoropyrimidine, irinotecan, and oxaliplatin between April 2014 and December 2019 3) detected BRAF V600E mutation in tumor tissue confirmed by real-time polymerase chain reaction (PCR), or next generation sequencing (NGS)

Exclusion criteria

Exclusion criteria: 1) patients with another concomitant cancer at the time of diagnosis

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results